Search results
Results from the WOW.Com Content Network
Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2 and EGFR: Medullary thyroid cancer. Diarrhoea, hypertension, QT interval prolongation, depression, electrolyte anomalies, hypothyroidism and GI perforation (uncommon). 2.3 mTOR inhibitors: Everolimus: PO: mTOR inhibitor.
Tissue factor pathway inhibitor (or TFPI) is a single-chain polypeptide which can reversibly inhibit factor Xa (Xa). While Xa is inhibited, the Xa-TFPI complex can subsequently also inhibit the FVIIa-tissue factor complex. TFPI contributes significantly to the inhibition of Xa in vivo, despite being present at concentrations of only 2.5 nM.
ovarian cancer, malignant ascites, gastric cancer cBR96-doxorubicin immunoconjugate: mab: humanized: Lewis-Y antigen: cancer Cedelizumab [47] mab: humanized: CD4: prevention of organ transplant rejections, treatment of autoimmune diseases Cemiplimab [32] Libtayo: mab: human: PD-1: Y: cutaneous squamous cell carcinoma Cergutuzumab amunaleukin ...
[1] [4] [2] It is a tissue factor pathway inhibitor (TFPI) antagonist. [4] It was developed by Pfizer. [5] Marstacimab is a new type of medication that, rather than replacing a clotting factor, works by reducing the amount, and therefore, the activity of, the naturally occurring anticoagulation protein called tissue factor pathway inhibitor. [4]
21789 Ensembl ENSG00000105825 ENSMUSG00000029664 UniProt P48307 O35536 RefSeq (mRNA) NM_006528 NM_001271003 NM_001271004 NM_009364 NM_001381907 NM_001381908 RefSeq (protein) NP_001257932 NP_001257933 NP_006519 NP_033390 NP_001368836 NP_001368837 Location (UCSC) Chr 7: 93.89 – 93.89 Mb Chr 6: 3.96 – 3.99 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Tissue factor pathway ...
Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor medication that is used in the treatment of breast cancer for post-menopausal women. [1]It was patented in 1986 and approved for medical use in 1996. [4]
Ipilimumab, in combination with nivolumab, is indicated for the treatment of adults and adolescents twelve years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Belzutifan, sold under the brand name Welireg, is an anti-cancer medication used for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. [9] [13] [14] [15] It is taken by mouth. [9] Belzutifan is an hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. [9] [11] [16]